详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

PROTACs in gastrointestinal cancers

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China [2]South SichuanInstitute of Translational Medicine, Luzhou 646000, China [3]Department of Oncology, The Affiliated Hospital of Southwest Medical University, Southwest MedicalUniversity, Luzhou 646000, China [4]Institute of Drug Clinical Trial/GCP Center, The Affiliated Hospital of Southwest Medical University, Southwest MedicalUniversity, Luzhou 646000, China [5]Department of Emergency, The Affiliated Hospital of Southwest Medical University, Southwest Medical University, Luzhou646000, China [6]Medical Cosmetology Center, Affiliated Hospital of Traditional Chinese Medicine, Southwest Medical University, Luzhou 646000, China [7]CellTherapy & Cell Drugs of Luzhou Key Laboratory, Southwest Medical University, Luzhou 646000, China

出处：

DOI：

ISSN：

摘要：

Proteolysis targeting chimera (PROTAC) presents a powerful strategy for targeted protein degradation (TPD). The heterobifunctional PROTAC molecule consists of an E3 ligase ligand covalently linked to a protein of interest (POI) via a linker. PROTAC can induce ubiquitinated proteasomal degradation of proteins by hijacking the ubiquitin-proteasome degradation system (UPS). This technique has the advantages of broad targeting profile, good cell permeability, tissue specificity, high selectivity, oral bioavailability, and controllability. To date, a growing number of PROTACs targeting gastrointestinal cancers have been successfully developed, and, in many cases, their POIs have been validated as clinical drug targets. To the best of our knowledge, 15 PROTACs against various targets are currently tested in clinical trials, and many more are likely to be added in the near future. Therefore, this paper details the mechanism, research progress, and application in clinical trials of PROTACs, and summarizes the research achievements related to PROTACs in gastrointestinal cancers. Finally, we discuss the advantages and potential challenges of PROTAC for cancer treatment.© 2022 The Authors.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 2 区医学

小类 | 2 区医学：研究与实验 3 区肿瘤学

最新[2023]版：

大类 | 2 区医学

小类 | 2 区医学：研究与实验 3 区肿瘤学

第一作者：

第一作者机构： [1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China [2]South SichuanInstitute of Translational Medicine, Luzhou 646000, China

共同第一作者：

通讯作者：

通讯机构： [3]Department of Oncology, The Affiliated Hospital of Southwest Medical University, Southwest MedicalUniversity, Luzhou 646000, China [6]Medical Cosmetology Center, Affiliated Hospital of Traditional Chinese Medicine, Southwest Medical University, Luzhou 646000, China [7]CellTherapy & Cell Drugs of Luzhou Key Laboratory, Southwest Medical University, Luzhou 646000, China [*1]Department of Oncology, The Affiliated Hospital of Southwest Medical University, Southwest Medical University, Luzhou 646000, China. [*2]Medical Cosmetology Center, Affiliated Hospital of Traditional Chinese Medicine, Southwest Medical University, Luzhou 646000, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：